Alveus Therapeutics: Valuation, Funding & Investors
Alveus Therapeutics is a clinical-stage biotechnology company developing next-generation therapies for obesity and metabolic diseases. The company focuses on programs designed for sustained efficacy, improved tolerability, and reduced treatment burden, including a bifunctional GIPR antagonist/GLP-1R agonist and an amylin-based portfolio spanning injectable and oral modalities.
Leadership & Board
- Current Number of Employees
- 35
- Current LinkedIn Followers
- 3,493
Latest Estimated Valuation
- Total Amount Raised
- $160M
- Total Funding Rounds
- 1
- Latest Funding Amount
- $160M
- Latest Funding Round
- Series A
Employee Trend
Alveus Therapeutics had 35 employees as of November 9, 2026. The number of employees increased by 0 (0.00%) week-over-week.
Social Trend
Alveus Therapeutics had 3,493 followers as of November 9, 2026. The number of followers increased by 29 (0.84%) week-over-week.
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Jan 08, 2026 | Series A | $159.80M | ― |
Investors
| Investor Name | Funding Round |
|---|---|
| Omega Funds | Series A |
| Avego Bioscience Capital | Series A |
| Andera Partners | Series A |
| Kurma Partners | Series A |
| New Rhein Healthcare Investors | Series A |
| Sanofi Capital | Series A |
Similar Companies
A snapshot of private companies similar to Alveus Therapeutics, helping you discover and navigate related company profiles.
